Raúl Teruel Montoya¹, Ginés Luengo Gil², Fernando Vallejo³, Jose Enrique Yuste³, NATALIYA BOHDAN ⁴, NURIA GARCÍA BARBERÁ¹, SALVADOR ESPÍN GARCÍA⁵, CONSTANTINO MARTÍNEZ GÓMEZ¹, Juan Carlos Espín³, Vicente Vicente García¹, IRENE MARTINEZ MARTINEZ¹

(1) HEMATOLOGÍA Y ONCOLOGÍA MÉDICA CLÍNICO-EXPERIMENTAL, IMIB, España
(2) PATOLOGÍA MOLECULAR Y FARMACOGENÉTICA, IMIB, España
(3) Servicio de Metabolómica, CEBAS-CSIC, 30100, Campus de Espinardo, España (Región de Murcia)
(4)
(5) FFIS, 30003, España (Región de Murcia)

PMID: 30837665
Referencia: Teruel-Montoya R, Luengo-Gil G, Vallejo F, Yuste JE, Bohdan N, García-Barberá N, Espín S, Martínez C, Espín JC, Vicente V, Martínez-Martínez I. Differential miRNA expression profile and proteome in plasma exosomes from patients with paroxysmal nocturnal hemoglobinuria. Sci Rep. 2019 Mar 5;9(1):3611. doi: 10.1038/s41598-019-40453-5. PubMed PMID: 30837665.
ISSN: 2045-2322
Revista: Scientific Reports
Factor de impacto (2017): 4.6
Cuartil: 2

Paroxysmal Nocturnal Hemoglobinuria (PNH) is a clonal disease of blood cells caused by the lack of glycosyl phosphatidyl inositol anchored proteins bound to the cell membrane. In consequence, erythrocytes lead to intravascular hemolysis upon complement activation, which promotes high risk of thrombosis, intravascular hemolytic anemia, and bone marrow failure in patients. The mechanisms of thrombosis in PNH are still poorly understood. Treatment with eculizumab reduces intravascular hemolysis and thrombotic risk, but not in all cases. Exosomes are extracellular vesicles released by cells and whose secretion is closely related to the inflammatory status. They participate in cell communication by activating signaling pathways and transferring genetic material and proteins to host cells. In consequence, exosomes may serve as surrogate biomarkers for the prognosis and/or diagnosis of a disease.

Exosome isolation, electron microscopy, miRNAs PCR panel, LC-MS analysis, qRT-PCR.

Isolation of exosomes was carried out from healthy controls and from three groups of PNH patients, i.e. i) with no eculizumab treatment; ii) under treatment with eculizumab that have not suffered thrombosis; and iii) under treatment with eculizumab but that have suffered thrombosis. The miRNAome and proteome was analyzed using plasma focus miRNAs PCR panel and LC-MS analysis respectively. We found differential expression of miRNAs miR-148b-3p, miR-423-3p, miR29b-3p, miR15b-5p, let-7e-5p, miR126-3p, miR-125b-5p and miR-376c-3p as well as hemoglobin, haptoglobin, protein S and C4-binding protein in healthy controls vs PNH patients.

Our results warrant further research and provide new information on the content of exosomes that could play a role in the hypercoagulable state in this disease.